Retroviral Gag proteins contain short late-domain motifs that recruit cellular ESCRT pathway proteins to facilitate virus budding. ALIX-binding late domains often contain the core consensus sequence YPX n L (where X n can vary in sequence and length). However, some simian immunodeficiency virus (SIV) Gag proteins lack this consensus sequence, yet still bind ALIX. We mapped divergent, ALIX-binding late domains within the p6 Gag proteins of SIV mac239 ( 40 SREKPYKEVTEDLLHLNSLF 59 ) and SIV agmTan-1 ( 24 AAGAYDPARKLLEQY AKK 41 ). Crystal structures revealed that anchoring tyrosines (in lightface) and nearby hydrophobic residues (underlined) contact the ALIX V domain, revealing how lentiviruses employ a diverse family of late-domain sequences to bind ALIX and promote virus budding.
Many enveloped viruses, including retroviruses, recruit proteins of the cellular ESCRT pathway to facilitate budding (reviewed in references 3, 11, and 35). Short sequence motifs, termed late domains, within retroviral Gag polyproteins bind directly to early-acting ESCRT factors, which then recruit and activate the downstream machinery necessary for membrane fission. The three well-characterized late domains are typically denoted by their canonical core amino acid sequences: PTAP late domains bind the ubiquitin E2 variant (UEV) domain of the TSG101 subunit of the ESCRT-I complex, PPXY late domains bind WW domains of NEDD4 family ubiquitin E3 ligases, and YPX n L (where X n can vary in sequence and length) late domains bind the V domain of ALIX (10, 20, 32, 37) . In a number of cases, retroviral Gag proteins have been shown to utilize multiple late domains (e.g., see references 3, 4, 7, 11, 16, 31, 33, 34, and 35) . We speculate that this phenomenon may be even more prevalent than is currently appreciated because mutations in auxiliary late domains often produce weak or cell-specific phenotypes and because late domains can be difficult to recognize owing to primary sequence divergence. It is therefore of interest to define the range of different sequences that can function as late domains and to learn how sequence variation is tolerated while late-domain function is retained.
Strack and colleagues initially reported that ALIX binds core sequences of 35 LYPLTSL 41 and 22 LYPDL 26 within the late domains of human immunodeficiency virus type 1 (HIV-1) p6
Gag and equine infectious anemia virus (EIAV) p9 Gag , respectively (32) (anchoring tyrosines are shown in boldface, and nearby hydrophobic residues that contact ALIX are underlined). They also reported that p6
Gag proteins from simian immunodeficiency virus SIV mac239 and SIV agmTan-1 can bind and package ALIX into virions, but in those cases the ALIXbinding sites were not fully mapped and were not obvious, because the SIV p6
Gag proteins lacked canonical YPX n L ALIX-binding elements. We therefore performed biosensor binding experiments and deletion analyses to quantify and map the ALIX-binding sites. These experiments employed a recombinant ALIX protein that spanned the Bro1 and V domains (residues 1 to 698), here denoted ALIX Bro1-V , but lacked the C-terminal proline-rich region (residues 699 to 868). As shown in Fig. 1 Gag and EIAV p9 Gag both contain key tyrosine residues that bind in a deep pocket on the second arm of the ALIX V domain (37) . The ALIX-binding sites within SIV mac239 and SIV agmTan-1 p6
Gag also contained single tyrosine residues (highlighted in boldface), and alanine point mutations in each of these tyrosines eliminated any detectable ALIX binding to the full-length SIV p6
Gag proteins (Fig. 1) . Thus, these tyrosines are also key determinants of ALIX binding to the SIV p6
Gag proteins. To learn how these SIV p6
Gag proteins recognize and recruit ALIX, we crystallized and determined the structures of ALIX Bro1-V (KK 268,269 YY mutant) in complex with bindingsite peptides from the SIV agmTan-1 and SIV mac239 p6
Gag proteins. Crystallization and data collection were performed as previously described (37) . Crystallographic statistics are provided in Table 1 . A comparison of the two SIV peptide complex structures with the previously reported HIV and EIAV late-domain complexes reveals that the ALIX protein structure is essentially invariant. In all cases, the dominant interaction is insertion of a tyrosine side chain of the p6 peptide into a deep hydrophobic pocket on ALIX (Fig. 2) . The tyrosines of all four late-domain peptides superimpose closely and make the same contacts with ALIX, including a hydrogen bond between the tyrosine phenoxyl and the conserved ALIX Asp506 side chain. As described previously, the EIAV and HIV late-domain interfaces also bury a proline immediately following the tyrosine (the Y ϩ 1 position) and a leucine at Y ϩ 3 (EIAV) or Y ϩ 5 (HIV), with the different leucine positions being accommodated by different conformations of the peptide backbone, either extended (EIAV, designated a type 1 ALIX-binding motif) or helical (HIV, designated type 2) from the Y ϩ 2 position.
The two SIV peptides form equivalent ALIX interfaces but do so by adopting yet another conformation (termed a type 3 ALIX-binding motif). In both cases, they are helical from the Y ϩ 1 residue, which results in the Y ϩ 3 Val/Ala and Y ϩ 7 Leu occupying the same locations as the Pro and Leu of EIAV and HIV (Fig. 2) . The most notable difference between the two SIV peptides is that their helices project at an angle of 15°with respect to each other. This presumably results from differences in residues that contact ALIX, especially Val versus Ala at position Y ϩ 3, and results in a 2.5-Å displacement of the SIV agmTan-1 Y ϩ 7 Leu compared to the structurally equivalent Leu of SIV mac239 , HIV, and EIAV. Thus, late-domain sequences adopt a range of conformations in order to preserve the interaction motif: ⌽YX 0/2 ⌽X 1/3 L, with the alternative 0/2 and 1/3 spacings of the intervening X residues accommodated by extended versus helical backbone conformations. a Data were collected at beam line X29 of the National Synchrotron Light Source and processed using HKL2000 (23) . The structures were determined using rigid-body refinement with the unliganded ALIX Bro1-V model and were refined in PHENIX (1) with TLS refinement (24, 25) . Model building was performed with O (17) and COOT (9) .
where ͗I͘ is the average intensity of multiple measurements. R factor ϭ ¥ hkl ͉͉F obs (hkl)͉͉ Ϫ F calc (hkl)͉͉/¥ hkl ͉F obs (hkl)͉. R free ϭ the cross-validation R factor for the 5% of reflections against which the model was not refined. Gag proteins. Samples were analyzed in triplicate. p6
Gag proteins, minimal binding peptides (blocked N and C termini), were created, and the binding studies were performed and analyzed as described previously (37) . RU, response units. (B) Representative biosensor binding isotherms for ALIX Bro1-V binding to SIV mac239 Gag or SIV agmTan-1 p6 Gag proteins. (C) Summary of ALIX Bro1-V dissociation constants for different retroviral p6/p9 proteins/peptides. Values for SIV peptides are the means from two independent experiments (each measured in triplicate) Ϯ ranges. Dissociation constants for the HIV-1 and EIAV peptides were reported previously (37) but are reprinted here for reference.
VOL. 85, 2011 NOTES 633 Sequence analyses revealed that nearly all primate lentiviruses carry one of the three different types of ALIX-binding motifs, supporting the idea that type 3 ALIX-binding motifs can function as late domains that enhance virus budding (Fig.  3A) . SIV mac239 p6
Gag has been analyzed by deletion analysis (26) , but unfortunately the functional importance of the key tyrosine residue in the ALIX-binding site was not tested. We therefore used a SIV mac251 -based system (21), for which a vector was available, to test whether noncanonical ALIX-binding sites within SIV p6
Gag proteins can function as late domains. SIV mac251 and SIV mac239 are closely related and have identical p6
Gag ALIX-binding sites. Both isolates also contain PTAP elements within p6
Gag that presumably bind TSG101 and function as late domains.
Constructs were designed to mutate key residues in both candidate late domains within the SIV mac251 p6
Gag proteins encoded by the pSIV3ϩ helper vector without altering the underlying Pol reading frame ( 11 PTAP 14 to 11 LIAL 14 , termed ⌬PTAP; and 38 EKPYKEVTEDLLHL 51 to 38 EKPSKEVTED SLHL 51 , termed ⌬YL; mutated residues are italicized). Virions were produced in 293T cells and analyzed as described previously (30) , with Western blotting used to detect virionassociated and cellular CA levels (anti-SIVmac CA mouse monoclonal antibody, 1:3,000 [14] ) and cellular ALIX levels (anti-ALIX rabbit polyclonal antibody, 1:5,000 [10] ). Viral titers were measured using flow cytometry to detect green fluorescent protein (GFP) expression from the packaged pSIVgaMES4sin vector in transduced 293T cells. As expected, the ⌬PTAP mutation inhibited SIV mac251 release, as measured by reductions in virion-associated CA (p27) protein levels (Fig. 3B, VIRION Western blot, compare lanes  1 and 2) , without altering cellular CA expression levels (CELL Gag (Protein Data Bank code 2R02; green), EIAV p9 Gag (Protein Data Bank code 2R03; turquoise), SIV mac239 p6 Gag (magenta), and SIV agmTan-1 p6
Gag (salmon). Panels A to C were generated using PyMOL (6) . (D) Late-domain peptide sequences used for crystallography and binding studies, aligned on the basis of the crystal structures. Residues modeled in the crystal structures are in boldface, and those lacking electron density are in italics. Residues that are structurally equivalent in all four complexes are highlighted by a gray background. Residues that bury more than 50% of their solvent-accessible surface at the protein interface are underlined. Note that ALIX binds three different types of viral sequence motifs, which we have designated types 1 to 3.
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NOTES J. VIROL. blot). Vector titers were also dramatically reduced, essentially to background levels [from 1.06 (Ϯ0.06) ϫ 10 6 /ml to 6 (Ϯ2) ϫ 10 3 /ml; 180-fold reduction] (Fig. 3B , bottom panel, compare lanes 1 and 2). SIV mac251 release and infectivity were also reduced by the ⌬YL mutation in the ALIX-binding site, although the reduction was much less dramatic than for the ⌬PTAP mutation (Fig. 3B, compare lanes 1 and 3; 3-fold infectivity reduction). The ⌬PTAP/⌬YL double mutation inhibited virus release to an even greater extent than either single mutation alone (Fig. 3B, compare lanes 2 and 4) , with viral titers again near background levels. Mutations in either (or both) late domains led to accumulation of the CA-SP1 processing intermediate within cells (Fig. 3B , CELL blot, compare lane 1 to lanes 2 to 4). This phenotype is also seen for HIV-1 late-domain mutants and is indicative of budding defects (13) . Thus, both the 11 PTAP 14 and 38 EKPYKEVTEDLL HL 51 sequences within SIV mac251 p6
Gag promote Gag processing, virion release, and viral infectivity, and the PTAP sequence serves as the dominant late domain under these experimental conditions. The situation is similar for HIV-1; both the ALIX-and TSG101-binding late domains are functional, but mutations in the PTAP element are more detrimental in most cell types (12) .
To confirm that the SIV mac251 p6
Gag 38 EKPYKEVTEDLL HL 51 late domain was ALIX responsive, we tested whether ALIX overexpression stimulated virus release via this sequence (10, 33) . ALIX overexpression did not alter the release and infectivity of wild-type SIV mac251 , presumably because the 11 PTAP 14 late domain was already highly active (Fig. 3B, compare lanes 1 and 5) . In contrast, ALIX overexpression substantially stimulated the release and infectivity of an SIV mac251 ⌬PTAP construct [to 1.4 (Ϯ0.2) ϫ 10 5 ; 23-fold infectivity increase] (Fig. 3B, compare lanes 2 and 6) . This stimulation was dependent upon the ALIX-binding site within SIV mac251 p6
Gag , because ALIX overexpression failed to stimulate either the ⌬YL or the ⌬PTAP/⌬YL mutant constructs significantly (compare lanes 3 to 7 and 4 to 8). Stimulation also required the YPX n L-binding site of ALIX, because an inactivating point mutation within this site (F676D) blocked the ability of ALIX to stimulate release of the ⌬PTAP construct (compare lanes 6 and 9). Thus, the 38 EKPYKEVTEDLLHL 51 site within SIV mac251 p6
Gag functions as an ALIX-dependent late domain.
FIG. 3. Primary sequences and functional analyses of the late domains within primate lentiviral p6 Gag proteins. (A) Maximum likelihood phylogenetic tree showing the different primate lentiviral lineages and their p6
Gag proteins (drawn to scale as white boxes). TSG101-binding P(S/T)AP late domains are shown in blue, and putative ALIX-binding late domains are shown in red (predicted ALIX contact residues) or black (solvent exposed residues). ALIX-binding-site types are designated at right (see text for explanation). Sequences that most closely match the crystallographically characterized ALIX complexes are denoted with stars. Consensus sequences for the designated lineage(s) were derived from reference 19, and residues conserved at Ͼ85% identity are shown in capital letters. p6
Gag proteins from the HIV-1/SIV cpz lineage fall into three different classes that either have type 1 or 2 ALIX-binding sites or lack apparent ALIX-binding sites (and also lack tyrosines). As shown in Fig. 3A , p6 Gag proteins from nearly every known primate lentiviral lineage contain a type 1, type 2, or type 3 ALIX-binding site, implying that (i) the ability to bind ALIX must provide primate lentiviruses with a strong selective advantage and (ii) these three types probably account for all (or nearly all) of the different ALIX-binding modes. The only exceptions are a subset of viruses within the HIV-1/SIV cpz lineage, which lack identifiable ALIX-binding sites, and possibly also a subset of SIV wrc viruses whose type 1 ALIX-binding sites have Trp in place of Tyr. Type 3 ALIX-binding sites are widespread throughout primate lentiviruses, and type 1 and 3 sites are more common than type 2 sites (which predominate only in HIV-1 strains). Interestingly, p6
Gag proteins that lack the ability to bind TSG101 typically have type 1 ALIX-binding sites (2) . Type 1 sites bind ALIX with relatively high affinities, at least in the cases examined to date (Fig. 1C) , and this correlation may therefore reflect a need to recruit ALIX more efficiently when TSG101 cannot be recruited directly.
Although ALIX binds rather weakly to most isolated late domains, several factors likely enhance ALIX recruitment in vivo. First, p6-ALIX V domain interactions of the type studied here can be augmented by upstream interactions between the ALIX Bro1 domain and the HIV-1 Gag NC domain (8, 28, 29) . Analogous SIV NC-ALIX Bro1 interactions are also possible, although such interactions alone are apparently not sufficient to stimulate virus release because ALIX overexpression does not substantially rescue SIV mac251 release or infectivity in the absence of the p6
Gag ALIX-binding site. Second, activated ALIX is dimeric (27) , which should enhance binding avidity to oligomeric Gag assemblies. Third, ALIX can associate with ubiquitin, and ubiquitylation of Gag (or associated proteins) could therefore enhance ALIX recruitment (18) . Finally, both Gag and ALIX can associate with membranes, which may increase the effective local ALIX concentrations at budding sites. Thus, relatively weak ALIX-p6
Gag interactions of the type described here are apparently sufficient to ensure that ALIX is recruited to function in virus budding.
Once recruited, ALIX can stimulate virus budding by recruiting the downstream ESCRT-III membrane fission machinery via direct interactions with CHMP4 subunits (10, 33) and also via additional stimulatory activities of the N-terminal Bro1 domain that may involve membrane deformation (28) . CHMP4 recruitment appears to be important in the case of SIV mac251 , because the ALIX I212D mutant, which cannot bind CHMP4 (22) , also failed to stimulate release of the ⌬PTAP construct (Fig. 3B, compare lanes 6 and 10) . Thus, the ALIXbinding site in SIV mac251 p6
Gag functions, at least in part, to provide access to the membrane fission activity of the downstream ESCRT-III proteins.
Our results also have important implications for the identification of cellular ALIX-binding partners. The YPX n L-binding site within the ALIX V domain presumably evolved to bind cellular partners, rather than viral late domains. To date, however, only one cellular interaction of this type has been identified: that between the Aspergillus ALIX homolog PalA and its binding partner PacC (36) . PalA binds tandem YPXL/I motifs within PacC that match canonical EIAV late domains, and this interaction facilitates the pH-regulated cleavage of the PacC transcription factor. Such pH-sensing pathways are not conserved outside of fungi, however, suggesting that additional ALIX-binding partners have yet to be identified. Our studies show that ALIX can bind a broader range of sequences than previously appreciated, requiring only an anchoring tyrosine interaction and downstream hydrophobic residues that can vary in both identity and spacing. Cellular ALIX-binding partners (and possibly also other viruses) can presumably also employ this very loose consensus motif, which may help explain why the mammalian ALIX-binding partner(s) has thus far escaped detection.
Protein structure accession numbers. Coordinates and diffraction data for ALIX Bro1-V (KK 268,269 YY mutant) in complex with the SIV mac239 and SIV agmTan-1 peptides have been deposited in the Protein Data Bank (PDB codes 2XS1 and 2XS8, respectively). 
